Ryan F. Robinson - 22 Oct 2025 Form 4 Insider Report for Tourmaline Bio, Inc. (TRML)

Role
CFO
Signature
/s/ Brad Middlekauff, Attorney-in-Fact
Issuer symbol
TRML
Transactions as of
22 Oct 2025
Net transactions value
+$199,975
Form type
4
Filing time
24 Oct 2025, 17:08:06 UTC
Previous filing
29 Jan 2025
Next filing
28 Oct 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Robinson Ryan F. CFO C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK /s/ Brad Middlekauff, Attorney-in-Fact 24 Oct 2025 0001997834

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TRML Common Stock Options Exercise $199,975 +14,366 $13.92 14,366 22 Oct 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRML Employee Stock Option (Right to Buy) Options Exercise $0 -14,366 -36% $0.000000 25,845 22 Oct 2025 Common Stock 14,366 $13.92 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option vested as to 25% of the shares on July 5, 2024 with the remainder vesting in the following 36 equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.